AZ Targets Viral Oncolytics With Transgene Development Deal

 
• By Jo Shorthouse

AstraZeneca inks a deal with French firm Transgene to co-develop five armed oncolytic vaccinia virus candidates in an area that is hotting up for big pharma.

LightBulbs
AZ will provide five molecules for development • Source: Shutterstock

More from R&D

More from Scrip